Armistice Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Armistice Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Buy	+6,733	New	+$199K	﹤0.01%	288
2022 Q3	–	Sell	-10,200,000	Closed	-$71.5M	–	207
2022 Q2	$71.5M	Buy	10,200,000 +1,828,000	+22%	+$13.4M	1.25%	18
2022 Q1	$69.4M	Sell	8,372,000 -1,200,000	-13%	-$8.48M	1.34%	14
2021 Q4	$64.8M	Sell	9,572,000 -428,000	-4%	-$2.81M	1.06%	23
2021 Q3	$53M	Hold	10,000,000	–	–	0.9%	24
2021 Q2	$57.5M	Hold	10,000,000	–	–	1.03%	24
2021 Q1	$46.1M	Hold	10,000,000	–	–	1.06%	30
2020 Q4	$33.4M	Hold	10,000,000	–	–	1.14%	26
2020 Q3	$29.7M	Buy	10,000,000 +3,800,000	+61%	+$14.9M	1.08%	34
2020 Q2	$28.6M	Buy	6,200,000 +800,000	+15%	+$3.59M	1.26%	28
2020 Q1	$20.8M	Buy	5,400,000 +300,000	+6%	+$1.23M	1.29%	33
2019 Q4	$19.1M	Buy	+5,100,000	New	+$23.8M	1.1%	31
2019 Q3	–	Sell	-5,000,000	Closed	-$19.2M	–	70
2019 Q2	$19.2M	Buy	5,000,000 +3,480,000	+229%	+$15M	1.21%	29
2019 Q1	$7.75M	Buy	1,520,000 +140,000	+10%	+$412K	0.42%	44
2018 Q4	$2.65M	Sell	1,380,000 -292,000	-17%	-$836K	0.2%	54
2018 Q3	$6.32M	Sell	1,672,000 -28,000	-2%	-$87.7K	0.38%	54
2018 Q2	$5.3M	Buy	+1,700,000	New	+$5.16M	0.35%	60

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital's CPRX Position: Q2 2026 in Review

Armistice Capital opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 6,733 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #288 among its holdings. This is a return to the name: Armistice Capital previously reported a position in CPRX as recently as Q2 2022.

Armistice Capital first reported a position in CPRX in Q2 2018 and has held it in 17 quarters since. The position peaked at $71.5M in Q2 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Armistice Capital held 6,733 shares of Catalyst Pharmaceutical worth $212K as of Q2 2026.
Catalyst Pharmaceutical was a new Armistice Capital position in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #288 holding.
Armistice Capital first reported a position in Catalyst Pharmaceutical in Q2 2018 and has held it in 17 quarters since.
Armistice Capital's Catalyst Pharmaceutical position peaked at $71.5M in Q2 2022.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.